الصفحة الرئيسية>>Apraglutide

Apraglutide (Synonyms: FE 203799)

رقم الكتالوجGC34473

Apraglutide (FE 203799) ، عبارة عن ببتيد صناعي مكون من 33 حمضًا أمينيًا وتناظرية GLP-2 طويلة المفعول ، يعزز التكيف ونمو الأمعاء الخطي في نموذج خنزير صغير حديثي الولادة لمتلازمة الأمعاء القصيرة مع استئصال كلي للدقاق

Products are for research use only. Not for human use. We do not sell to patients.

Apraglutide التركيب الكيميائي

Cas No.: 1295353-98-8

الحجم السعر المخزون الكميّة
1mg
108٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum[1].

Apraglutide (FE 203799; 5 mg/kg/dose, subcutaneously, twice on days 0 and 4 postsurgery) treated piglets are healthy, have significant lower fecal fat and energy losses and exhibite intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth on day 7[1]. Animal Model: NewbornDuroc piglets, 2-5 days old and weighing between 2-2.6 kg[1].

[1]. Slim GM, et al. Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. JPEN J Parenter Enteral Nutr. 2019 Jan 6.

مراجعات

Review for Apraglutide

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Apraglutide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.